Trending Investment Opportunities
Advertisement
- The FDA has approved Roche Holdings AG's RHHBY Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with Pfizer Inc's (NYSE: PFE) Lorbrena (lorlatinib).
- The assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue.
- It is indicated as an aid in identifying patients eligible for treatment with PFE's Xalkori (crizotinib), Novartis AG's (NYSE: NVS) Zykadia (ceritinib), Roche's Alecensa (alectinib), or Lorbrena in the U.S.
- Price Action: RHHBY shares closed 1.2% lower at $40.12 on Monday.
Loading...
Loading...
NVSNovartis AG
$116.74-0.61%
Edge Rankings
Momentum
67.39
Growth
27.95
Quality
38.96
Value
26.25
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: